Your AZD6738-Boost Makes The New PF-562271 Procedure So Exciting

However, the median laboratory WBC counts were similar between the two groups, even when the 100-day patient group converted to placebo for the later 100 days. Furthermore, the incidences of reported neutropenia, febrile neutropenia, agranulocytosis, anemia, thrombocytopenia and pancytopenia were comparable between the two groups. The majority of leukopenia cases resolved with or without treatment or study medication adjustment. However, 4% of patients (7/156) in the 200-day group had leukopenia that led to discontinuation of study medication compared with http://www.selleckchem.com/products/VX-765.html grade 3 or 4 according to their laboratory values. Overall, the use of granulocyte-colony stimulating factor (G-CSF) was similar between the two groups 14% (22/156) versus 13% (22/164). The incidence of neutropenia was comparable between the groups overall and from study day 100 onward, when patients in the day-100 group were taking placebo tablets (15% in both groups overall [Table 3], and 5% (n = 8) in the 200-day group and 3% (n = 5) in the 100-day group after study day 100). The incidence of gastrointestinal disorders in the two groups was 61% (95/156) and 52% (85/164), respectively, with the majority being diarrhea (Table 3). Interestingly, the incidence of gastrointestinal disorders was similar from study day 100 onward, when patients in the 100-day group were taking placebo tablets (21% (32/156) and 19% (31/164) in the http://www.selleck.cn/products/azd6738.html two groups, respectively). Table 4 summarizes the common adverse events (occurring in ��5% in either group) experienced from study day 100 onward in both groups. The proportion of patients in the ITT population with confirmed opportunistic infection (other than CMV disease) up to 12 months posttransplant was significantly lower in 200-day group http://www.selleckchem.com/products/pf-562271.html (p = 0.001; Table 2). This difference appears mainly due to an imbalance in occurrence of opportunistic infection during the first 50 days of therapy (0%[0/155] vs. 31.8%[14/163] of the overall opportunistic infections in the 200 days vs. 100 days groups, respectively). The proportion of patients with confirmed posttransplantation diabetes mellitus was similar (p = 0.815) between the groups up to month 12 (Table 2). While the number of hospitalizations and the duration of the hospitalization stay were comparable between the groups (Table 5), the number of hospitalizations due to CMV was lower in the 200-day group (10% vs. 21%). All patients in the 200-day group survived to Month 12 posttransplant, but there were four deaths in the 100-day group, which were considered to be unrelated to study medication. Two patients died of septic shock on days 96 and 229 posttransplant, respectively, one patient died on day 335 posttransplant due to hemorrhage, and one patient died of sepsis on day 169 posttransplant.